Epic.Cd

EPIC.CD maintains a conservative capital structure with a debt-to-equity ratio of 0.12, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 3.17, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, which could signal potential liquidity constraints in the near term.

In terms of profitability, EPIC.CD's return on equity (ROE) is 1.68%, and its return on assets (ROA) is 1.16%. These figures are below the industry median for ROE and ROA, which are typically higher in the pharmaceutical sector due to the high margins associated with drug development and sales. The company's operating income of CAD 713,850 and net income of CAD 484,850 reflect modest profitability, which may be attributed to the high costs of research and development in the pharmaceutical industry.

EPIC.CD's revenue is concentrated in a few key therapeutic areas, with a particular focus on oncology and rare diseases. The company's geographic exposure is primarily North American, with a significant portion of its revenue derived from the United States. This concentration may expose the company to regulatory and market risks specific to these regions.

The company's growth trajectory is expected to remain modest, with the current fiscal year (FY) outlook indicating a slight increase in revenue. The next FY is projected to show a similar trend, with the company aiming to maintain its market position through the continued development of its pipeline products. The company's capital expenditure of CAD -250,600 suggests a focus on maintaining existing operations rather than expanding aggressively.

Risk factors for EPIC.CD include the potential for dilution, although the risk is currently assessed as low. The company's dilution potential is minimal, with no significant changes in shares outstanding between basic and diluted shares. However, the company's liquidity risk is moderate, primarily due to its negative net cash position after accounting for total debt. Credit risk is also a concern, given the company's reliance on short-term financing and the potential for increased interest rates to impact its financial stability.

Recent events, including filings and transcripts, indicate that EPIC.CD is focused on advancing its drug candidates through clinical trials and securing regulatory approvals. The company has also been engaging in strategic partnerships to enhance its research and development capabilities. These activities are expected to support the company's long-term growth and innovation in the pharmaceutical sector.